Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.32 |
| ▸ | CBX7 | O95931 | 1/20 | 0.32 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.32 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294189 | 1.00 | ALDH1A1 (0.34) | ALDH1A1HTTKMT2AUSP30NPC1 | |
| SCHEMBL15069645 | 0.92 | KDM2B (0.34) | ALDH1A1HTTKMT2AUSP30NPC1 | |
| SCHEMBL10182417 | 0.90 | KMT2A (0.41) | ALDH1A1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL15773712 | 0.90 | KMT2A (0.41) | ALDH1A1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL15586735 | 0.90 | KMT2A (0.41) | ALDH1A1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL12752017 | 0.90 | KMT2A (0.41) | ALDH1A1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL1293616 | 0.89 | L3MBTL1 (0.41) | ALDH1A1KMT2AUSP30NPC1L3MBTL1 | |
| SCHEMBL1293617 | 0.89 | L3MBTL1 (0.41) | ALDH1A1KMT2AUSP30NPC1L3MBTL1 | |
| SCHEMBL10234338 | 0.86 | ALDH1A1 (0.41) | ALDH1A1HTTKMT2ANPC1RAB9A | |
| SCHEMBL1294135 | 0.85 | BACE1 (0.38) | ALDH1A1KMT2AUSP30NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499127-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-07-16 | — | — | US | disclosed |
| US-9006455-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006455-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130317213-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | ALDH1A1 1107/4885HTT 4547/4885KMT2A 4482/4885 |
| US-20130317213-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | ALDH1A1 1627/4885HTT 4745/4885KMT2A 4479/4885 |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885HTT 4592/4885KMT2A 4516/4885 |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885HTT 4592/4885KMT2A 4516/4885 |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | ALDH1A1 1627/4885HTT 4745/4885KMT2A 4479/4885 |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885HTT 4592/4885KMT2A 4516/4885 |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885HTT 4592/4885KMT2A 4516/4885 |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885HTT 4592/4885KMT2A 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.